bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract B26: [Advocate Abstract:] We all win
Authors: Fields Frank D. 
Published: February 2019

Abstract
To gain long-term survivorship joint interest among the survivor-patient, family-spouse, children, siblings, friends, with an engaging medical community that creates trust for both patient and family are keys to long-term success. After treatment has completed, do both patient and family members understand that long-term success depends on continued follow-up? I have observed that patients after initial treatment make a conscious decision to curtail medical treatment. Cost and quality of life along with no longer wanting to be a burden to patients' family are key issues. The prostate survivor when still with the family is a gift that strengthens the family and is priceless. Continually turning to the medical community after treatment enhances life. Another issue is patients who are 5 years and beyond with their treatment who have health concerns that in part can be related to cancer therapies. These patients choose watchful waiting. We as Health Advocates have to promote continued health care to post-treated patients. We have to nurture and foster families that what is good for Dad is good for them.
Citation Format: Frank D. Fields. [Advocate Abstract:] We all win [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B26.
Abstract B30: [Advocate Abstract:] Health disparities among Latinos with pancreatic cancer
Authors: Zelada-Arenas Fatima 
Published: February 2019

Abstract
The purpose of this project is to examine health disparities and quality of care received by Latino patients with pancreatic cancer. We connect with many Spanish speakers through our Patient Services program and will be conducting interviews to determine the level of care Latino patients are receiving. We are hoping to identify if they have any issues with accessing cancer care, whether they are being seen in a community oncology center, and how often they experience insurance access issues. The goal is to determine the needs of this very specific community to help us understand how to best guide them and provide them with resources.
Citation Format: Fatima Zelada-Arenas. [Advocate Abstract:] Health disparities among Latinos with pancreatic cancer [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B30.
Abstract B46: Vorinostat modulates the expression of the progesterone receptor in subtypes of triple-negative breast cancer cell lines
Authors: Lyn-Cook Beverly , NouriEmamzadeh Fatemeh , Word Beverly , Moore Rhonda , Miranda-Carboni Gustav 
Published: February 2019

Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by a lack of clinically significant levels of hormone receptors for estrogen (ER) and progesterone (PR) and the human epidermal growth factor receptor-2 (HER2). TNBC has a high cell proliferation rate and has been described as an “interval cancer,” developing between yearly mammograms. TNBC accounts for 10-15% of all breast cancers diagnosed, and risk factors include age (&gt; 40) and mutational status of tumor-suppressor genes (p53, BRCA1). Additionally, Hispanic American, African American, and women of African descent have been shown to be 3x more likely to develop this more aggressive subtype. The lack of cell surface receptors for ER, PR, and Her2 makes these tumors unresponsive to conventional hormone or targeted therapy, and currently there are no FDA-approved targeted therapies for this disease. This, combined with a higher rate of relapse and shorter overall survival period, leads to an overall poor prognosis for this breast cancer subtype. Vorinostat is a histone deacetylase inhibitor and has been shown to exert effects through epigenetic mechanisms. Previous studies have shown its ability to re-express ERα in triple-negative breast cancer cells. In this study we examined whether Vorinostat can re-express the PR in subtypes of TNBC cell lines HCC70, HCC1143, HCC1806, and BT549 and render these resistant cells sensitive to cancer agents. Using real-time PCR and immunostaining, the re-expression of the PR receptor was shown in BT549 (4-fold), HCC70 (13-fold), HCC 1143 (5-fold), and HCC1806 (20-fold). PR is known to modulate ERα in breast cancer. Indole-3-carbinol (I3C) alone or in combination with tamoxifen decreased PR expression in HCC1806 and HCC70 cells. Tamoxifen and I3C also inhibited cell growth of triple-negative breast cancer cells with vorinostat. These results show promise for the use of vorinostat in sensitizing subtypes of triple-negative breast cancer cells to tamoxifen and a dietary agent, I3C. Furthermore, this study revealed that vorinostat can re-express critical receptors in triple-negative breast cancer, suggesting its possible use in combinational therapy for this aggressive form of breast cancer.
Citation Format: Beverly Lyn-Cook, Fatemeh NouriEmamzadeh, Beverly Word, Rhonda Moore, Gustav Miranda-Carboni. Vorinostat modulates the expression of the progesterone receptor in subtypes of triple-negative breast cancer cell lines [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B46.
Abstract B53: Psychosocial stress exposure results in inhibition of mammary gland development and increased mammary stem cells in a rat model of breast cancer
Authors: Johnson Marianna B. , Hoffmann Joscelyn N. , You Hannah M. , Allaw Ahmad B. , Strober Jordan W. , Brady Matthew J. , McClintock Martha K. , Conzen Suzanne D. 
Published: February 2019

Abstract
Exposure to unremitting psychosocial stressors common to underserved populations (i.e., social marginalization and isolation, economic uncertainty, and racism) manifest in physiologic changes that are associated with highly aggressive mammary cancer. Many environmental exposures that influence breast cancer risk in adulthood occur earlier in life during the time of mammary gland development. However, the effect of stress physiology on mammary gland development and its link to breast cancer remains unknown. In a model of psychosocial stress (social isolation), we studied whether a social isolation-induced stress response would affect mammary gland development. To this end, we used the Sprague Dawley rat, where there is an established effect of psychosocial stress on increasing later-life mammary cancer risk. Here, we found that post-weaning social isolation was associated with decreased ductal differentiation and increased mammary stem cells (MaSC). Using an in vitro model, we next determined if glucocorticoid receptor activation increased MaSC survival through direct and paracrine mechanisms. Our findings provide evidence that social stressors induce glucocorticoid exposure and decrease mammary gland differentiation leading to an increased MaSC population, potentially contributing to a greater mammary cancer risk.
Citation Format: Marianna B. Johnson, Joscelyn N. Hoffmann, Hannah M. You, Ahmad B. Allaw, Jordan W. Strober, Matthew J. Brady, Martha K. McClintock, Suzanne D. Conzen. Psychosocial stress exposure results in inhibition of mammary gland development and increased mammary stem cells in a rat model of breast cancer [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B53.
Abstract B58: The role of epigenetic reader and alternative mRNA splicing variant MBD2_v2 in IL6 signaling in prostate cancer
Authors: Girsch Emily , Bao Bin , Mitrea Cristina , Sakr Wael A. , Dyson Gregory , Powell Isaac , Bollig-Fischer Aliccia 
Published: February 2019

Abstract
Background: African American men (AAM) have a 60% higher risk of being diagnosed with prostate cancer and a 2 to 3 times greater risk of dying from the disease compared to European American men (EAM). We previously reported evidence of molecular underpinnings for these disparities from high-throughput gene expression analysis of prostate cancer (PCa) specimens. The data showed that proinflammatory cytokine signaling factors, including IL6 and TGFB1, are significantly over-represented in PCa specimens from AAM. The limitation of that study, however, is that it did not investigate the potential molecular diversity for high-grade PCa, and it did not consider adjacent noncancer tissue.
Methods: We conducted a pilot RNA-sequencing study of high-grade PCa, GS greater or equal to 7(4+3), and matched non-cancer adjacent prostate tissue specimens from AAM and EAM. We also studied the molecular biology of PCa cell lines derived from AAM and EAM tumors.
Results: According to our genomic analysis, IL6 was once again relevant to our research, this time upregulated in PCa specimens from EAM, but also higher in the stromal compartment in AAM. Also, we noted that whether or not a PCa cell line expresses IL6 appears to be linked to TP53 mutation status. Moreover, cell lines derived from AAM (MDA-PCa-2b and RC77T), which are TP53 wild-type, did not express IL6 and showed an increased stem cell-like phenotype in response to IL6 treatment that was dose dependent. PCa cell lines that are TP53 mutant and expressed IL6 did not respond to exogenous IL6 treatment. We uncovered that in responsive PCa cell lines, IL6 treatment induced mRNA and protein expression of the epigenetic reader methyl CpG binding domain protein 2 (MBD2), more specifically the alternative mRNA splicing variant MBD2_v2. Further investigation validated that this short isoform promotes self-renewal and expansion of PCa stem cell-like cells.
Conclusion: The outcomes suggest that there may be a dual nature for IL6 signaling in PCa that remains to be understood, yet contributes to the molecular diversity of high-grade prostate cancer and race disparities.
Citation Format: Emily Girsch, Bin Bao, Cristina Mitrea, Wael A. Sakr, Gregory Dyson, Isaac Powell, Aliccia Bollig-Fischer. The role of epigenetic reader and alternative mRNA splicing variant MBD2_v2 in IL6 signaling in prostate cancer [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B58.
Abstract B75: Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells
Authors: Stampouloglou Eleni , Kingston Nathan , Yang Chih-Sheng , Zhang Liye , Monti Stefano , Varelas Xaralabos 
Published: February 2019

Abstract
The aberrant activity of the transcriptional regulators TAZ and YAP (TAZ/YAP) drives many oncogenic traits, including the resistance to cell death, sustaining cell growth, and control of cell fate. Aggressive breast cancers in particular exhibit high TAZ/YAP levels and activity, and thus understanding the roles of these factors may offer therapeutic opportunity for these poorly treatable diseases. Here, we report that TAZ/YAP play an important role in driving breast cancer dependency to exogenous glutamine, an abundant amino acid that has emerged as central for tumor growth. We observed that breast cancer cells with high levels of TAZ/YAP are more sensitive to glutamine deprivation, and that knockout of TAZ/YAP in these cells alleviated defects resulting from glutamine. Rescue experiments with glutamine-derived metabolites suggested an essential role for glutamate and α-ketoglutarate (AKG) in TAZ/YAP-driven cell growth. Analysis of enzymes mediating the conversion of glutamate to α-ketoglutarate (AKG) showed that TAZ/YAP induce the expression of distinct transaminases, and that TAZ/YAP activity positively correlates with transaminase expression in breast cancer patients. Notably, the transaminase inhibitor aminooxyacetate (AOA) repressed cell growth in a TAZ/YAP-dependent manner, identifying transamination as a potential vulnerable metabolic requirement for TAZ/YAP-driven breast cancer. Considering the link between breast cancer risk and obesity, and the connection between obesity-driven metabolic changes to glutamine metabolism, our study offers a potential direction for future therapeutic targeting of aggressive breast cancers in underserved populations, where obesity is becoming a prevalent factor.
Citation Format: Eleni Stampouloglou, Nathan Kingston, Chih-Sheng Yang, Liye Zhang, Stefano Monti, Xaralabos Varelas. Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B75.
Abstract B91: [Advocate Abstract:] Metastatic patients and clinical trials
Authors: Knowles April 
Published: February 2019

Abstract
Clinical trials have the potential to extend and possibly save lives. But they are not readily accessible to patients with metastatic cancer. They place undue burdens on patients, employ restrictive eligibility requirements, and do not reflect the perspective of the metastatic population, making it difficult to impossible for patients to participate in appropriate, convenient trials in a timely manner. Clinical trials are often the last resort for metastatic patients, who have exhausted all “standard of care” options. Yet, for that very reason, metastatic patients are typically excluded from most clinical trials.
Citation Format: April Knowles. [Advocate Abstract:] Metastatic patients and clinical trials [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B91.
Abstract C33: [Advocate Abstract:] The power of music
Authors: Foster William 
Published: February 2019

Abstract
As a musician I feel that music has healing powers. There are Music Therapy Departments in many major hospitals and there has been a lot a research done on the subject. I think there need to be more. The poster explains some of the research that has been done and the results of the research.
Citation Format: William Foster. [Advocate Abstract:] The power of music [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr C33.
Abstract C70: A community guide systematic review of multicomponent interventions to increase breast, cervical, and colorectal cancer screening: Findings in underserved populations
Authors: Okasako-Schmucker Devon , Peng Yinan , Sabatino Susan , Ramon Ismaila , Roberts Kristin Tansil , Mercer Shawna L. , Elder Randy 
Published: February 2019

Abstract
Background: Underserved adults are disproportionately not up-to-date with cancer screening. This systematic review examined effectiveness of multicomponent interventions (MCIs) to increase breast, cervical, and colorectal cancer (CRC) screening. Special attention was paid to underserved populations and interventions that engage community health workers (CHWs) and patient navigators (PNs).
Methods: This systematic review consists of studies in high-income countries with eligible screening outcomes (recent or repeat mammography, Pap test, or CRC screening). Summary effects were calculated and stratified by income, insurance, involvement of Federally Qualified Health Centers (FQHCs) or community health centers (CHCs), and involvement of CHWs and PNs.
Results: Eighty-eight studies were included. Among majority low-income populations, MCIs increased breast (median increase 10.5 percentage points (pp), interquartile interval (IQI) 6.5-25.7; 10 arms), cervical (median 7.0 pp, IQI 5.3-58.9; 7 arms), and CRC screening (median 15.5 pp, IQI 6.9-23.6; 13 arms). Screening use increased among majority uninsured populations across all three cancers (median 31.8 pp, range 23.2-40; 3 arms). MCIs involving FQHCs or CHCs increased breast and cervical (median 7.0 pp, IQI 2.3-11.0; 5 arms) and CRC screening (median 16.3 pp, IQI 13.9-23.8; 8 arms). Interventions engaging CHWs and PNs among low-income, majority-uninsured populations, or those utilizing FQHCs or CHCs also increased screening use across all three cancer types combined (CHWs: median 15.5 pp, IQI 5.8-60.1; 10 arms; PNs: median 11.9 pp, IQI 7.0-15.5; 11 arms).
Conclusions: MCIs targeting underserved populations are effective in increasing breast, cervical, and CRC screening. MCIs engaging CHWs and PNs are effective among these populations.
Citation Format: Devon Okasako-Schmucker, Yinan Peng, Susan Sabatino, Ismaila Ramon, Kristin Tansil Roberts, Shawna L. Mercer, Randy Elder. A community guide systematic review of multicomponent interventions to increase breast, cervical, and colorectal cancer screening: Findings in underserved populations [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr C70.
Abstract C84: African Americans' perceived benefits and barriers to colorectal cancer screening: Differences by screening modality
Authors: Williams Randi M. , Holt Cheryl L. 
Published: February 2019

Abstract
Background: Perceived benefits and barriers are key individual-level factors that play a role in colorectal cancer (CRC) screening behavior. Utilizing data harmonized from three CRC screening trials, we examine how measures of benefits and barriers by screening type (colonoscopy and fecal occult blood test (FOBT)) predict preintervention screening behaviors among African American (AA) trial participants.
Methods: The data were collected in AA churches (Study 1: N=103; Study 2: N=285; Study 3: N=374) where trained lay community health advisors conducted CRC education to increase screening.
Results: In Study 1, colonoscopy benefits were associated with greater odds of being adherent to CRC screening at baseline (p=.03), while colonoscopy barriers were not significant. FOBT benefits/barriers were not significantly related to screening at baseline. For Study 2, individuals who perceived more colonoscopy benefits were more likely to be adherent (p=.01), whereas those with more perceived barriers were less likely to be adherent at baseline (p=.04). FOBT benefits/barriers were not significant. In Study 3, FOBT benefits positively predicted FOBT screening behavior and barriers were negatively associated with screening (p's=.01 and .02, respectively). Colonoscopy benefits were marginally significant (p=.06) such that individuals with higher benefits were more likely to report screening, whereas perceived barriers were not related to screening.
Conclusions: In the present data, perceived benefits and barriers more consistently predicted preintervention screening behavior for colonoscopy relative to FOBT. Additional study is needed to evaluate the role of benefits/barriers in CRC screening behavior in response to interventions.
Citation Format: Randi M. Williams, Cheryl L. Holt. African Americans' perceived benefits and barriers to colorectal cancer screening: Differences by screening modality [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr C84.
Abstract IA05: Research addressing cervical cancer disparities: Progress, challenges, and opportunities
Authors: Paskett Electra D. 
Published: February 2019

Abstract
In 2007, disparities in cervical cancer incidence and mortality were evident among black vs white women, Hispanic vs non-Hispanic women, and rural vs non-rural women. Reasons for these disparities include lack of Pap testing, inappropriate follow-up after an abnormal test, and high rates of infection with high-risk human papillomavirus (HPV). In 2017, these disparities still exist. While early detection tests for cervical cancer have been available since the late 1950s, prevention of cervical cancer began with the identification of HPV as a necessary cause for cervical cancer and the subsequent development, testing, and approval of the HPV vaccine in 2006 for girls and 2011 for boys. Uptake of the vaccine in age-eligible girls and boys has been slow in the US, with better uptake--and a complementary reduction in HPV infection and preinvasive cervical abnormalities--in other countries such as Australia, the United Kingdom, and Rwanda. Screening guidelines have been updated to focus on more appropriate age and cotesting with HPV cytology.
Challenges are apparent in assuring that rates of uptake of the vaccine series approach the 80% threshold set by the CDC for all populations. Moreover, rates of appropriate screening--including the new guidelines for cotesting--are challenging to maintain, as there is confusion regarding these guidelines among both patients and providers. Appropriate follow-up after an abnormal Pap test remains a problem, with lower follow-up among minority, low-income, and rural populations.
There are many opportunities for increasing the uptake of the HPV vaccine series, appropriate screening, and prompt and proper follow-up of abnormalities in populations experiencing disparities. Several areas of investigation show promise and deserve further exploration. These include: one vs two/three doses of the HPV vaccine; HPV self-testing strategies to increase adherence to screening; and use of “see and treat” strategies to assure follow-up and treatment of cervical abnormalities in low-resource settings. In addition, creative and culturally appropriate multilevel intervention approaches should be tested to increase adherence in populations suffering from disparities.
Strategies to increase adherence to HPV vaccine series, screening, and follow-up recommendations can make a significant reduction in cervical cancer incidence and mortality disparities.
Citation Format: Electra D. Paskett. Research addressing cervical cancer disparities: Progress, challenges, and opportunities [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA05.